Form 4: Director Ross Acquires LMAT Dividend Rights

Lemaitre Vascular Director Bridget A. Ross reported the acquisition of dividend equivalent rights tied to her restricted stock and performance share units.

Summary

• Bridget A. Ross, a Director at Lemaitre Vascular Inc. (LMAT), reported changes in her beneficial ownership.
• The filing details the acquisition of several tranches of Dividend Equivalent Rights (DERs) on March 26, 2026.
• These DERs are linked to previously granted Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Each DER is economically equivalent to one share of Lemaitre Vascular's common stock and vests proportionately with the underlying awards.
• The acquired DERs include 0.3941, 0.472, 0.6426, 0.7276, and 1.2077 units, corresponding to awards granted on December 8, 2023, December 6, 2024, and December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine disclosure of director compensation and equity award mechanics, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• The acquisition of Dividend Equivalent Rights indicates ongoing equity participation and alignment of a director's interests with shareholders.
• The vesting of these rights suggests continued employment and performance, as they vest proportionately with the underlying RSU and PSU awards.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the vesting schedule of the dividend equivalent rights, which is tied to existing equity awards.

Industry Context

StockSavvy.ai notes that the granting and vesting of dividend equivalent rights as part of executive compensation packages are standard practices across many industries, particularly in companies that use restricted stock units and performance share units to incentivize long-term performance and align management interests with shareholders. This filing reflects a routine aspect of director compensation.

Comparison to Industry Standards

• The use of Dividend Equivalent Rights (DERs) tied to Restricted Stock Units (RSUs) and Performance Share Units (PSUs) is a common practice in executive and director compensation across the medical device and broader healthcare industry, similar to companies like Medtronic (MDT) or Stryker (SYK) which also utilize equity-based incentives.
• The vesting structure, where DERs vest proportionately with the underlying awards, aligns with typical industry standards designed to encourage long-term commitment and performance.

Related Party Transactions

• The acquisition of dividend equivalent rights by a director is inherently a related party transaction as part of executive compensation.

Stakeholder Impact

• Shareholders: The filing indicates ongoing alignment of a director's interests with shareholders through equity-based compensation.

Next Steps

• Continued vesting of the underlying Restricted Stock Unit and Performance Share Unit awards, to which these dividend equivalent rights are tied.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to director compensation, specifically the accrual of dividend equivalent rights tied to existing equity awards. Such a disclosure is standard and does not provide new information that would fundamentally alter the investment thesis for Lemaitre Vascular Inc. Therefore, a "hold" recommendation is appropriate as it neither signals a significant positive catalyst nor a material negative development.

Keywords

Lemaitre Vascular, LMAT, Bridget A. Ross, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Director Compensation, Equity Compensation